Objective To increase the sensitivity of residual leukemic cells detectin in chronic myelocytic leukemia(CML) patients with RT-PCR,the optional annealing temperature and PCR cycles were studied to confirm bcr-abl fused gene types,and bcr-abl mRNA transcripts were monitored by RQ-PCR to study the relation with CML at different phases. Methods Through changing the PCR conditions, the annealing temperature was measured from 55℃ to 60℃, and the number of reaction cycles was increased from 30 to 45.All 22 samples were examined, and bcr-abl mRNA transcripts were quantified by RQ-PCR kit. Results Bcr-abl fused gene types were found in 22 samples,of all 9 cases were b_2a_2 type, 13 cases were b_3a_2.When the annealing temperature was set for 58℃ and the number of reation cycles was set for 45,10~3 copies/ul standard samples was detected.18 samples were positive tested by RQ-PCR kit,and the value was between 10~2 to 10~6 copies/g.There were significant differce between the results of chronic phase samples and those of accelerated phase. Conclusions The RT-PCR is a reliable,sensitive and reproducible method of monitoring CML patients.The real-time RT-PCR is useful in evaluating leukemic burden,assessing response to treatment and predicating the prognosis of the disease.

Objective:To explore the level changes and clinical significance of peripheral blood fibrinogen (FIB) and its degradation products (FDP) in patients with multiple myeloma (MM).Methods:One hundred and two MM patients who treated in Tongling People's Hospital from January 2015 to April 2018 were selected and divided into good prognosis group and poor prognosis group according to the prognosis. The correlation between the levels of FIB and FDP in peripheral blood and prognosis and the predictive value of poor prognosis were analyzed, and the survival was analyzed.Results:The ratio of tumor cells in bone marrow, international staging system (ISS) stage, and the levels of serum hemoglobin, albumin, creatinine, and β2-microglobulin in good prognosis group and poor prognosis group had significant differences ( P<0.05). The levels of peripheral blood FIB and FDP in the poor prognosis group and after 3 cycles of chemotherapy were higher than those in the good prognosis group: before chemotherapy: (4.71 ± 0.68) g/L vs. (4.02 ± 0.65) g/L, (50.56 ± 9.14) mg/L vs. (37.52 ± 8.25) mg/L; after 3 cycles of chemotherapy: (4.15 ± 0.62) g/L vs. (3.42 ± 0.53) g/L, (42.28 ± 9.51) mg/L vs. (6.59 ± 1.60) mg/L, there were statistical differences ( P<0.05). Controlled other factors after chemotherapy, the peripheral blood FIB and FDP of 1 cycle, 3 cycles of chemotherapy were still significantly related to the prognosis ( P<0.05). The area under the curve value of the combination of peripheral blood FIB and FDP before chemotherapy was 0.852, which was greater than independent detection of any index. The 2-year survival rate of patients with high levels of FIB and FDP were lower than those of patients with low levels ( P<0.05). Conclusions:Peripheral blood FIB and FDP of MM patients are independent risk factors that affect the prognosis. An increase in their levels indicates a poor prognosis. Clinical treatment can be actively improved according to the changes in the levels of the two to ensure the maximum benefit for patients.